Literature DB >> 28219794

Atrial fibrillation in hypertrophic cardiomyopathy: A turning point towards increased morbidity and mortality.

Thomas Zegkos1, Georgios K Efthimiadis2, Despoina G Parcharidou2, Thomas D Gossios2, Georgios Giannakoulas2, Dimitris Ntelios2, Antonis Ziakas2, Stelios Paraskevaidis2, Haralambos I Karvounis2.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmic event in patients with hypertrophic cardiomyopathy (HCM). The aim of this study was to identify the clinical impact and prognostic significance of AF on a large cohort of patients with HCM.
METHODS: Echocardiographic and clinical correlates, risk factors for AF and thromboembolic stroke and the prognostic significance of AF were evaluated in 509 patients with an established diagnosis of HCM.
RESULTS: A total of 119 patients (23.4%) were diagnosed with AF during the index evaluation visit. AF patients had a higher prevalence of stroke and presented with worse functional impairment. Left atrial diameter (LA size) was a common independent predictor of the arrhythmia (OR: 2.2, 95% CI 1.6-3.3) and thromboembolic stroke (OR: 1.6, 95% CI 1.01-2.40). AF was an important risk factor for overall mortality (HR=3.4, 95% CI: 1.7-6.5), HCM-related mortality (HR=3.9, 95% CI: 1.8-8.2) and heart failure-related mortality (HR=6.0, 95% CI: 2.0-17.9), even after adjusting for statistically significant clinical and demographic risk factors. However, AF did not affect the risk for sudden death.
CONCLUSIONS: LA size is an independent predictor of both AF and thromboembolic stroke. Moreover, patients with AF, regardless of type, have significantly higher mortality rates than patients without AF.
Copyright © 2017 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  atrial fibrillation; hypertrophic cardiomyopathy; left atrium; morbidity; mortality

Mesh:

Year:  2017        PMID: 28219794     DOI: 10.1016/j.hjc.2017.01.027

Source DB:  PubMed          Journal:  Hellenic J Cardiol        ISSN: 1109-9666


  5 in total

1.  The predictive value of left ventricular and left atrial mechanics for atrial fibrillation and heart failure in hypertrophic cardiomyopathy: a prospective cohort study.

Authors:  Thomas Zegkos; Dimitris Ntelios; Despoina Parcharidou; Sotiris Katranas; Theofilos Panagiotidis; Christos A Papanastasiou; Efstratios Karagiannidis; Pavlos Rouskas; Vassilis Vassilikos; Haralampos Karvounis; Georgios K Efthimiadis
Journal:  Int J Cardiovasc Imaging       Date:  2021-04-05       Impact factor: 2.357

Review 2.  Thromboembolism in Patients with Hypertrophic Cardiomyopathy.

Authors:  Lu Liu; Zheng Liu; Xiaoping Chen; Sen He
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

3.  Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real-World Data.

Authors:  Benjamin J R Buckley; Stephanie L Harrison; Dhiraj Gupta; Elnara Fazio-Eynullayeva; Paula Underhill; Gregory Y H Lip
Journal:  J Am Heart Assoc       Date:  2021-11-15       Impact factor: 5.501

4.  Hypertrophic cardiomyopathies requiring more monitoring for less atrial fibrillation-related complications: a clustering analysis based on the French registry on hypertrophic cardiomyopathy (REMY).

Authors:  Marion Hourqueig; Guillaume Bouzille; Albert Hagège; Erwan Donal; Mariana Mirabel; Olivier Huttin; Thibaud Damy; Fabien Labombarda; Jean-Christophe Eicher; Philippe Charron; Gilbert Habib; Patricia Réant
Journal:  Clin Res Cardiol       Date:  2021-05-27       Impact factor: 5.460

Review 5.  Deciphering hypertrophic cardiomyopathy with electrocardiography.

Authors:  Thomas Gossios; Konstantinos Savvatis; Thomas Zegkos; Dimitrios Ntelios; Pavlos Rouskas; Despoina Parcharidou; Haralambos Karvounis; Georgios K Efthimiadis
Journal:  Heart Fail Rev       Date:  2021-07-21       Impact factor: 4.654

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.